Breaking News
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. To learn more, please visit www.pfizer.com.

Health Care Professionals Log In

Prescribing LYBREL®

Now that LYBREL is available, you may offer an FDA-approved combination oral contraceptive (COC) that provides highly effective pregnancy protection with the potential for some women to achieve amenorrhea over time.1,2 You may wish to discuss this option with your patients.

Selecting Patients
LYBREL may not be appropriate for every woman. Here are some helpful guidelines to consider when discussing LYBREL with your patients.

Discussing Therapy with Your Patients
Prepare for discussions with your patients about LYBREL with these answers to common questions.

Starting Therapy
Information on how to get a patient started on LYBREL, including how to use the convenient ClickCase™, and what a patient on LYBREL should do if she misses one or more pills.

Helping Patients Remember to Take Their Pills
Tips to help your patients remember to take LYBREL at the same time every day.

Tracking Breakthrough Bleeding
A patient’s body will go through an adjustment while taking LYBREL, which will likely include breakthrough bleeding and spotting. We’ve provided a useful, printable resource for patients to track their breakthrough bleeding.

Important Safety Information

  • Oral contraceptives (OCs) do not protect against HIV infection or other sexually transmitted diseases.
  • When prescribing LYBREL, the convenience of having no scheduled menstrual bleeding should be weighed against the inconvenience of unscheduled breakthrough bleeding and spotting.
  • OCs are contraindicated in women who have blood clots; breast, uterine, or liver cancers; a history of heart attack, stroke, or breast cancer; as well as those who are or may be pregnant.
The risks of serious cardiovascular side effects are substantially increased in women who smoke and use OCs, especially in women over age 35. Women who use oral contraceptives should be strongly advised not to smoke.
  • Serious risks associated with OCs include blood clots, heart attack, and stroke.
  • LYBREL provides women with more hormonal exposure on a yearly basis (13 additional weeks of hormone intake per year) than conventional cyclic oral contraceptives containing the same strength of synthetic estrogens and similar strength of progestins.
  • Scheduled withdrawal bleeding does not occur with the use of LYBREL, therefore, the absence of withdrawal bleeding cannot be used as a sign of an unexpected pregnancy and as such, unexpected pregnancy may be difficult to recognize. Although pregnancy is unlikely if LYBREL is taken as directed, if for any reason, pregnancy is suspected in a woman using LYBREL, a pregnancy test should be performed.
  • The most commonly reported treatment emergent adverse events reported with LYBREL in a clinical trial were headache, dysmenorrhea, upper respiratory infection, vaginal bleeding (defined as metrorrhagia and vaginal hemorrhage), and nausea.

Registration | Unsubscribe | E-mail This Page | Patient Awareness | References

236749-01

LYBREL and LYBREL with icon are registered trademarks of Wyeth.